T1	intervention 50 56	EP2006
T2	control 87 107	reference filgrastim
T3	condition 183 201	severe neutropenia
T4	eligibility 205 272	patients with breast cancer receiving myelosuppressive chemotherapy
T5	eligibility 525 656	patients with breast cancer receiving (neo)adjuvant myelosuppressive chemotherapy (TAC; docetaxel + doxorubicin + cyclophosphamide)
T6	No-of-participants 815 818	218
T7	intervention-participants 1477 1480	109
T8	control-participants 1514 1516	52
T9	outcome 1618 1633	incidence of FN
T10	outcome-Measure 1345 1375	febrile neutropenia (FN) rates
T11	control-value 1638 1640	0%
T12	intervention-value 1660 1664	3.4%
T13	intervention-value 1670 1671	3
T14	outcome 1799 1809	Infections
T15	intervention-value 1822 1826	9.3%
T16	control-value 1845 1849	9.9%
T17	outcome 1863 1888	Hospitalisation due to FN
T18	intervention-value 1898 1901	one
T19	outcome 1933 1947	Adverse events
T20	intervention-value 1987 1992	42.1%
T21	control-value 2011 2016	39.2%
T22	outcome 2043 2086	Musculoskeletal/connective tissue disorders
T23	intervention-value 2121 2126	35.5%
T24	control-value 2145 2150	39.2%
T25	outcome 2222 2245	neutralising antibodies
